Replies to post #1410 on Idenix Pharmaceuticals (IDIX)

[DewDiligence]

3Q07 Hepsera sales: $79.1M (a $316M annualized rate),
+44% vs 3Q06 and +5% vs the prior quarter.

http://biz.yahoo.com/bw/071018/20071018006061.html?.v=1

The global HBV market continues to grow at a rapid rate. BMY will report 3Q07 Baraclude sales next week.